Short answer
As of November 2026, a telehealth brand can name Ozempic, Wegovy or Zepbound in ads only once certified: Google requires telemedicine providers to be certified regardless, Meta treats a named prescription drug as promotion needing LegitScript and its authorization, and trademark risk applies on top. MedScale Health, a paid ads agency for US telehealth brands and clinics, generally keeps branded drug names out of paid creative, because the traffic rarely justifies the exposure. An in-person clinic may name the drugs in US Google ads without certification but not keyword-target them.
Why is naming a GLP-1 brand in an ad two problems, not one?
Founders usually ask about Ozempic or Wegovy in ads as a single question, but there are two distinct exposures and they have different remedies. MedScale works with telehealth brands and clinics, and separating them is the first step to deciding sensibly.
- Trademark. Ozempic, Wegovy, Zepbound and Mounjaro are registered marks owned by their manufacturers, who actively police use by third parties.
- Advertising policy. Platforms restrict the promotion of prescription medication, particularly by advertisers who are not the manufacturer or an authorized dispenser.
A brand can clear the platform rules and still face the trademark question, which is why platform approval is not evidence that the usage is safe.
What is the trademark risk of naming Ozempic or Wegovy in ads?
Referential use means naming another company's mark only to describe your own offer accurately. Trademark law permits some referential use, and a business may generally use a mark to accurately describe what it offers. The principle is narrower than marketers assume, and it does not extend to usage that suggests affiliation, endorsement, or that the advertiser supplies the branded product when it does not.
The platforms handle marks differently. Google's trademark policy does not restrict trademarks used as keywords, but after a trademark owner's complaint it can restrict a mark in ad text, for example where the use is confusing or misleading, with exceptions for resellers and informational pages. Meta's Advertising Standards prohibit ads that violate a third party's trademark. The realistic risk is not an abstract legal argument but a demand letter arriving at a growth-stage company, so trademark use is a question for counsel rather than for a media plan. MedScale sends any use of a manufacturer's mark to the client's counsel before it reaches an ad.
Google's Editorial policy update for October 2026, posted October 1, adds a rule on business names: third-party resellers, affiliate distributors and secondary sellers may not use the standalone brand name of the goods they offer as their business name. The business name on a telehealth brand's Google ads should be its own, never Ozempic, Wegovy or Zepbound.
Do Google and Meta allow ads that name Wegovy or Zepbound?
Platform rules on prescription drugs differ, and Google's changed on October 29, 2025. Google's restricted drug terms policy for the United States now says certification is not needed to use prescription drug terms in ads and landing pages, but is needed to keyword-target them, and that online pharmacies, telemedicine providers and pharmaceutical manufacturers must be certified regardless. Meta lets only LegitScript-certified, authorized advertisers promote prescription drugs, to adults in the United States, Canada or New Zealand, with a consult-a-professional disclaimer.
For a telehealth brand, naming Wegovy in an ad is prescription-drug promotion on both platforms, so it waits for certification. An in-person clinic can now name the drug in Google ad text and on its landing page, but still cannot bid on the name as a keyword without certification. MedScale keeps drug names out of a telehealth brand's ads until certification and authorization are in place.
There is also a misrepresentation dimension. Where a brand names a branded medication in creative but a patient may be prescribed a different formulation, the mismatch between the ad and what is actually supplied is its own problem. FDA's March 2026 warning letters to 30 telehealth companies cited claims implying sameness with FDA-approved products, and its June 2026 guidance says compounded drugs must not be described as equivalent to approved ones. Naming the brand next to a compounded product is the most direct way to imply exactly that.
Update, November 9, 2026: an FDA warning letter dated October 30, 2026 cited a telehealth company's "Explore GLP-1s like Ozempic" profile line on X and a pinned video about "drugs like Ozempic", and said disclaimers that a compounded preparation "may not itself be FDA-approved" "do not cure the misleading overall impression created by these claims." MedScale Health keeps brand-drug comparisons out of compounded GLP-1 ads and landing pages.
Is branded GLP-1 search traffic worth buying?
The commercial argument for using branded names is that the demand exists and is enormous. The demand does exist, and the traffic it produces converts poorly for telehealth brands that cannot supply the branded product, because the intent is specific and the offer does not match it.
MedScale generally advises against branded drug names in paid creative for this reason as much as the legal one. The traffic is expensive, poorly matched, and arrives attached to two forms of risk. MedScale's free growth audit marks every branded drug name in a GLP-1 account's ads, keywords and landing pages, so the written plan starts from a complete list.
What should GLP-1 ads say instead of a drug brand name?
The workable alternatives describe the mechanism, the clinical program, or the category rather than the brand. Program language matches what the business actually provides, attracts patients whose expectations can be met, and sidesteps both exposures. MedScale writes GLP-1 ads around the program, the clinician and the mechanism for that reason.
- Describe the clinical program and who it is designed for.
- Refer to the drug class or mechanism in general terms where accurate.
- Let the intake process establish what an individual patient may be eligible for, rather than the ad.
Common questions
- 01Can I bid on branded GLP-1 keywords in search?
- Only with Google's certification. Keyword-targeting a prescription drug term such as Ozempic needs certification in the United States, and telemedicine providers need certification to serve prescription drug service ads at all. Google's trademark policy does not restrict marks as keywords, but the drug-term rule does, and trademark owners can still act, so take the decision with legal advice.
- 02Is it acceptable to say our program is an alternative to Ozempic?
- Avoid it. Comparative framing that references a mark to position your own product is precisely the usage most likely to draw the manufacturer's attention, because it invokes the brand's reputation. Describing the program on its own terms achieves the same commercial goal with materially less exposure.
- 03What if a patient asks about branded medication during intake?
- The clinician can answer. Clinical conversation between a patient and a prescriber sits in a different context from advertising, and clinicians can discuss medications appropriately. The constraint is on how the business promotes itself publicly, not on what a clinician may say inside a consultation.
- 04Do these restrictions apply outside the United States?
- Not identically. Trademark rights and pharmaceutical advertising rules are both national and vary considerably, with many countries prohibiting direct-to-consumer prescription drug advertising altogether. Each market needs to be assessed separately rather than inferred from United States practice.
Sources
- 01Google Ads policy: Restricted drug termschecked October 5, 2026
- 02Google Ads policy: Trademarkschecked October 5, 2026
- 03Google Ads policy: Update to Editorial Policy (October 2026), posted Oct 1, 2026checked October 12, 2026
- 04Meta Advertising Standards: Drugs and Pharmaceuticalschecked October 5, 2026
- 05Meta Advertising Standards: Introductionchecked October 5, 2026
- 06FDA press announcement (Mar 3, 2026): FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1schecked October 5, 2026
- 07FDA (Jun 15, 2026): FDA to telehealth companies, what to know when promoting compounded drugschecked October 5, 2026
- 08FDA warning letter to a telehealth company, MARCS-CMS 737905 (Oct 30, 2026), compounded semaglutide and tirzepatide claimschecked November 9, 2026
Related answers
Can You Advertise GLP-1 on Facebook and Instagram?
As of November 2026, GLP-1 telehealth brands can advertise on Facebook and Instagram to adults 18 and over if no copy implies the viewer's body or health; a prescription GLP-1 also needs LegitScript certification and Meta's authorization. MedScale, a paid ads agency for US telehealth brands and clinics, builds GLP-1 creative against those rules from the first concept, because accounts are lost to a pattern of disapprovals, not one banned claim. Since July 22, 2026, Meta judges before-and-after imagery by the claims around it.
Reviewed November 9, 2026
What Are the Rules for Advertising Compounded Semaglutide in 2026?
As of November 2026, compounded semaglutide can be advertised only on much narrower ground than during the shortage. MedScale Health, a paid ads agency for US telehealth brands and clinics, rewrites claims built on the shortage-era footing and labels compounded semaglutide as compounded, not FDA-approved. FDA resolved the semaglutide shortage on February 21, 2025, enforcement discretion ended in April and May 2025, and FDA's June 15, 2026 guidance tells telehealth companies not to present compounded drugs as generic, equivalent or FDA-approved.
Reviewed November 9, 2026
Can You Advertise GLP-1 on Google Ads?
As of October 2026, a GLP-1 telehealth brand can advertise on Google Ads once it holds LegitScript accreditation and Google's certification, which Google requires before prescription drug service ads serve in the United States. MedScale Health, a paid ads agency for US telehealth brands and clinics, sequences certification, then landing pages, then keywords. An in-person clinic may name semaglutide or tirzepatide in US ad text and landing pages without certification since October 29, 2025, but needs certification to keyword-target those terms.
Reviewed October 24, 2026
Last reviewed November 9, 2026. Platform policies change often; we re-verify every answer quarterly.